Objectives: To adapt and validate the Latin-Spanish version of the Self-Efficacy to Manage Chronic Disease (SEMCD-S) for the Chilean population.
Material And Methods: Twenty-one individual cognitive interviews were conducted with adults with diagnosed chronic diseases, comparing the understanding of the SEMCD-S with the Chilean adaptation (SEMCD-S-Ch) using paraphrasing and follow-up probes. Then, 144 adults with diagnosed chronic diseases under control were recruited in three family health centers in La Florida and La Pintana. These participants were administered the SEMCDS-Ch at recruitment, at six weeks, and four months later. An exploratory factor analysis (EFA) was conducted, the internal consistency of the instrument was calculated, and a confirmatory factor analysis (CFA) was performed to validate the EFA findings.
Main Results: The adaptation process incorporated changes in the writing style and some terms used in the SEMCD-S, improving the understanding of the instrument. In the psychometric testing of the SEMCDS-Ch, the AFE identified a single-factor solution, the internal consistency in each of the administrations was very good (α between 0.849 to 0.878), and the CFA confirmed the unidimensional structure of the instrument relatively well.
Conclusions: The SEMCD-S-Ch is understandable, reliable, and useful for a brief and competent assessment of self-efficacy in people with chronic diseases under control in primary health care.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4067/s0034-98872023001201596 | DOI Listing |
Proc Natl Acad Sci U S A
January 2025
Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN 47405.
Dysregulation of GABAergic inhibition is associated with pathological pain. Consequently, enhancement of GABAergic transmission represents a potential analgesic strategy. However, therapeutic potential of current GABA agonists and modulators is limited by unwanted side effects.
View Article and Find Full Text PDFPain
February 2025
Norwegian Centre for Addiction Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Blood
January 2025
Stanford University Medical Center, Stanford, California, United States.
Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy limited by graft-versus-host disease (GVHD). In preclinical studies and early-phase clinical studies enrichment of donor regulatory T cells (Tregs) appears to prevent GVHD and promote healthy immunity.We enrolled 44 patients on an open-label, single-center, phase 2 efficacy study investigating if a precision selected and highly purified Treg cell therapy manufactured from donor mobilized peripheral blood improves one-year GVHD-free relapse free survival (GRFS) after myeloablative conditioning (trial NCT01660607).
View Article and Find Full Text PDFPLoS One
January 2025
Key Laboratory of Sports Engineering of General Administration of Sport of China, Wuhan Sports University, Wuhan, Hubei Province, China.
Purpose: Previous studies have demonstrated significant biomechanical differences between individuals with chronic ankle instability (CAI) and healthy controls during the Y-balance test. This study aimed to examine the effects of kinesio taping (KT) on lower limb biomechanical characteristics during the Y-balance anterior reach task in individuals with CAI.
Methods: A total of 30 participants were recruited, comprising 15 individuals with CAI and 15 healthy controls.
J Bras Nefrol
January 2025
Universidade Estadual Paulista, Faculdade de Medicina, Departamento de Clínica Médica, Botucatu, SP, Brazil.
Introduction: Unplanned initiation of renal replacement therapy (RRT) in chronic kidney disease (CKD) patients is a common situation worldwide. In this scenario, peritoneal dialysis (PD) has emerged as a therapeutic option compared to hemodialysis (HD). In planned RRT, the costs of PD are lower than those of HD; however, the literature lacks such analyses when initiation is urgent.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!